XML 82 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1

Accrued expenses

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Accrued expenses

Accrued expenses

Accrued expenses consisted of the following (in thousands):

						December 31,
						2023						2022
Clinical trial and other development costs						$	752					$	12,314
Professional fees, listing and general corporate costs						2,039						1,364
People related costs						794						74
Total accrued expenses						$	3,585					$	13,752

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration